AUS
NZ
UK
CA
USA
IND
Highlights
Positive Phase I/II Results for FLT201: Spur Therapeutics presented encouraging data from the GALILEO-1 study, where five out of six patients treated with FLT201, a gene therapy for Gaucher disease, showed promising efficacy results.
Favorable Safety Profile: FLT201 showed a favorable safety profile with no infusion reactions, dose-limiting toxicities, or severe adverse events reported. This suggests the gene therapy is well-tolerated among patients.
Potential Breakthrough for Gaucher Disease: The results highlight FLT201's potential as an effective treatment for Gaucher disease, with long-term reductions in biomarkers and improvements in patient outcomes.
Syncona Ltd (LSE:SYNC), a prominent life science investor dedicated to creating and scaling global leaders in the sector, has highlighted positive results from its portfolio company Spur Therapeutics. Spur recently presented new data from its Phase I/II GALILEO-1 study of FLT201, a novel gene therapy candidate aimed at treating Gaucher disease, at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress in Rome, Italy.
Positive Study Results
In the GALILEO-1 study, six patients received a single infusion of FLT201 at a dose of 4.5e11 vg/kg, with follow-ups ranging from seven to 15 months post-dosing. Notably, five of the six patients exhibited promising efficacy results, while one patient was excluded from efficacy analyses due to the presence of detectable pre-existing neutralizing antibodies to the AAVS3 capsid used for delivering the therapy. However, all six patients were included in the safety analysis, where FLT201 showed a favorable safety and tolerability profile.
Key Findings
As of 27 September 2024, the study's findings underscored the potential of FLT201 as a viable treatment option for Gaucher disease, reflecting Spur’s robust technological capabilities. Highlights from the data include:
- Safety Profile: No infusion reactions, dose-limiting toxicities, or severe adverse events were reported, indicating a favorable safety profile for FLT201.
- Durable Reductions in Biomarkers: The therapy resulted in durable reductions in lyso-Gb1 levels, an established biomarker for clinical response in Gaucher disease, showing reductions ranging from 42% to 96% in patients who had persistently high levels despite years on enzyme replacement therapy (ERT) or substrate reduction therapy (SRT). Notably, one patient maintained low lyso-Gb1 levels for over a year following the withdrawal of prior treatments.
- Improvements in Bone Marrow Burden: All five patients demonstrated significant improvements in bone marrow burden, suggesting that FLT201 penetrates deeper tissues that current treatments inadequately address.
- Organ Volume Maintenance: Improvements or stabilization in spleen and liver volumes were observed, crucial for the management of Gaucher disease.
- Hemoglobin and Platelet Levels: The study also reported the maintenance of hemoglobin levels, a key endpoint in Gaucher disease trials, up to a year post-withdrawal from ERT or SRT. Improvement or maintenance of platelet counts was also recorded during this period.
Implications for Gaucher Disease Treatment
The publishing of these results marks a pivotal moment for Spur Therapeutics, reinforcing the therapeutic potential of FLT201 for patients suffering from Gaucher disease. This promising data not only underscores the effectiveness of FLT201 but also highlights the strength of Spur's innovative gene therapy technology.
As Syncona continues to support Spur Therapeutics and its mission to advance cutting-edge treatments in the life sciences, the results from the GALILEO-1 study signal a significant step forward in addressing the unmet medical needs of Gaucher disease patients. The company is well-positioned to further develop FLT201, potentially offering a new hope for those affected by this genetic disorder.
